



## Rasha 123

22/11/2024 05:11:01

### Main Information

**Primary registry identifying number**

LBCTR2018090151

**Protocol number**

Rasha123

**MOH registration number**

20555/2018

**Study registered at the country of origin**

Yes

**Study registered at the country of origin: Specify**

**Type of registration**

Prospective

**Type of registration: Justify**

N/A

**Date of registration in national regulatory agency**

15/09/2018

**Primary sponsor**

Rasha

**Primary sponsor: Country of origin**

Lebanon

**Date of registration in primary registry**

22/04/2020

**Date of registration in national regulatory agency**

15/09/2018

**Public title**

Rasha 123

**Acronym**

RH

**Scientific title**

Rasha 123

**Acronym**

RH

**Brief summary of the study: English**

Great Job

**Brief summary of the study: Arabic**

السجل الوطني للأبحاث السريرية  
الأول من نوعه

**Health conditions/problem studied: Specify**

Heart Failure

**Interventions: Specify**

New medication

**Key inclusion and exclusion criteria: Inclusion criteria**

all adults

**Key inclusion and exclusion criteria: Gender**

Both

**Key inclusion and exclusion criteria: Specify gender**

**Key inclusion and exclusion criteria: Age minimum**

18

**Key inclusion and exclusion criteria: Age maximum**

75



**Key inclusion and exclusion criteria: Exclusion criteria**

less than 18

**Type of study**

Observational

**Type of intervention**

Pharmaceutical

**Type of intervention: Specify type**

pharmaceutical with behavioral

**Trial scope**

Therapy

**Trial scope: Specify scope**

N/A

**Study design: Allocation**

Non-randomized controlled trial

**Study design: Masking**

N/A

**Study design: Control**

Uncontrolled

**Study phase**

1 to 2

**Study design: Purpose**

Treatment

**Study design: Specify purpose**

N/A

**Study design: Assignment**

Other

**Study design: Specify assignment**

single arm

**IMP has market authorization**

No

**IMP has market authorization: Specify**

USA

**Name of IMP**

In Love

**Year of authorization**

2014

**Month of authorization**

4

**Type of IMP**

Others

**Pharmaceutical class**

heart diseases

**Therapeutic indication**

to treat heart failure

**Therapeutic benefit**

increase ejection fraction

**Study model**

Case-Control

**Study model: Explain model**

OK

**Study model: Specify model**

N/A

**Time perspective**

Prospective

**Time perspective: Explain time perspective**

**Time perspective: Specify perspective**

N/A



OK

**Target follow-up duration**

30

**Target follow-up duration: Unit**

Months

**Number of groups/cohorts**

4

**Biospecimen retention**

Samples without DNA

**Biospecimen description**

DNA saliva samples

**Target sample size**

1000

**Actual enrollment target size**

1

**Date of first enrollment: Type**

Anticipated

**Date of first enrollment: Date**

20/10/2018

**Date of study closure: Type**

Anticipated

**Date of study closure: Date**

20/10/2020

**Recruitment status**

Complete

**Recruitment status: Specify**

**Date of completion**

24/04/2020

**IPD sharing statement plan**

No

**IPD sharing statement description**

I do not want to share

**Additional data URL**

later

**Admin comments**

**Trial status**

Approved



## Secondary Identifying Numbers

No Numbers

## Sources of Monetary or Material Support

No Sources

## Secondary Sponsors

No Sponsors

## Contact for Public/Scientific Queries

No Contacts

## Centers/Hospitals Involved in the Study

No Centers/Hospitals

## Ethics Review

No Reviews

## Countries of Recruitment

No Countries



## Health Conditions or Problems Studied

No Problems Studied

## Interventions

No Interventions

## Primary Outcomes

No Outcomes

## Key Secondary Outcomes

No Outcomes



## Trial Results

**Summary results**

**Study results globally**

**Date of posting of results summaries**

**Date of first journal publication of results**

**Results URL link**

**Baseline characteristics**

**Participant flow**

**Adverse events**

**Outcome measures**

**URL to protocol files**